Jung Yun Julie Kang, MD, PhD

Head and Neck Neoplasms; Prostatic Neoplasms

• Evaluation of Substantial Reduction in Elective Radiotherapy Dose and Field in Patients With Human Papillomavirus-Associated Oropharyngeal Carcinoma Treated With Definitive Chemoradiotherapy.Tsai CJ, McBride SM, Riaz N, Kang JJ, Spielsinger DJ, Waldenberg T, Gelblum D, Yu Y, Chen LC, Zakeri K, Wong RJ, Dunn L, Pfister DG, Sherman EJ, Lee NY. Evaluation of Substantial Reduction in Elective Radiotherapy Dose and Field in Patients With Human Papillomavirus-Associated Oropharyngeal Carcinoma Treated With Definitive Chemoradiotherapy. JAMA Oncology 2022, 8: 364-372. PMID: 35050342, PMCID: PMC8778604, DOI: 10.1001/jamaoncol.2021.6416.
• TERT Promoter Mutations Are Enriched in Oral Cavity Cancers and Associated With Locoregional Recurrence.Yu Y, Fan D, Song X, Zakeri K, Chen L, Kang J, McBride S, Tsai CJ, Dunn L, Sherman E, Katabi N, Dogan S, Cracchiolo J, Cohen M, Boyle JO, Lee M, Valero C, Wang J, Wong R, Morris L, Riaz N, Lee N. TERT Promoter Mutations Are Enriched in Oral Cavity Cancers and Associated With Locoregional Recurrence. JCO Precision Oncology 2021, 5 PMID: 34381934, PMCID: PMC8345918, DOI: 10.1200/PO.20.00515.
• Toxicity Profiles and Survival Outcomes Among Patients With Nonmetastatic Nasopharyngeal Carcinoma Treated With Intensity-Modulated Proton Therapy vs Intensity-Modulated Radiation Therapy.Li X, Kitpanit S, Lee A, Mah D, Sine K, Sherman EJ, Dunn LA, Michel LS, Fetten J, Zakeri K, Yu Y, Chen L, Kang JJ, Gelblum DY, McBride SM, Tsai CJ, Riaz N, Lee NY. Toxicity Profiles and Survival Outcomes Among Patients With Nonmetastatic Nasopharyngeal Carcinoma Treated With Intensity-Modulated Proton Therapy vs Intensity-Modulated Radiation Therapy. JAMA Network Open 2021, 4: e2113205. PMID: 34143193, PMCID: PMC8214161, DOI: 10.1001/jamanetworkopen.2021.13205.
• Any day, split halfway: Flexibility in scheduling high-dose cisplatin-A large retrospective review from a high-volume cancer center.Kang JJ, Tchekmedyian V, Mohammed N, Rybkin A, Kitpanit S, Fan M, Wang H, Lobaugh SM, Zhang Z, Lee A, Chen L, Yu Y, Zakeri K, Gelblum DY, Riaz N, McBride SM, Tsai CJ, Cohen MA, Cracchiolo JR, Morris LG, Singh B, Patel S, Ganly I, Boyle JO, Wong RJ, Eng J, Zhi WI, Ng K, Ho AL, Dunn LA, Michel L, Fetten JV, Pfister DG, Lee NY, Sherman EJ. Any day, split halfway: Flexibility in scheduling high-dose cisplatin-A large retrospective review from a high-volume cancer center. International Journal Of Cancer. Journal International Du Cancer 2021, 149: 139-148. PMID: 33586179, DOI: 10.1002/ijc.33518.
• Impact of Telemedicine on Patient Satisfaction and Perceptions of Care Quality in Radiation Oncology.Shaverdian N, Gillespie EF, Cha E, Kim SY, Benvengo S, Chino F, Kang JJ, Li Y, Atkinson TM, Lee N, Washington CM, Cahlon O, Gomez DR. Impact of Telemedicine on Patient Satisfaction and Perceptions of Care Quality in Radiation Oncology. Journal Of The National Comprehensive Cancer Network : JNCCN 2021, 19: 1174-1180. PMID: 33395627, PMCID: PMC8254817, DOI: 10.6004/jnccn.2020.7687.
• Outcomes and prognostic factors of major salivary gland tumors treated with proton beam radiation therapy.Zakeri K, Wang H, Kang JJ, Lee A, Romesser P, Mohamed N, Gelblum D, Sherman E, Dunn L, Boyle J, Wong R, Chen L, Yu Y, Tsai CJ, McBride SM, Riaz N, Lee N. Outcomes and prognostic factors of major salivary gland tumors treated with proton beam radiation therapy. Head & Neck 2021, 43: 1056-1062. PMID: 33606323, DOI: 10.1002/hed.26563.
• The effect of short radiation treatment breaks on chemo-radiotherapy for oropharyngeal cancers.Rybkin A, Kang JJ, Lee A, Kitpanit S, Fan M, Mohamed N, Cartano O, Zakeri K, Gelblum D, Sherman E, Dunn L, Boyle J, Wong R, Chen L, Yu Y, McBride SM, Tsai CJ, Riaz N, Lee NY. The effect of short radiation treatment breaks on chemo-radiotherapy for oropharyngeal cancers. Head & Neck 2021, 43: 3796-3809. PMID: 34585792, DOI: 10.1002/hed.26879.
• Platinum-based regimens versus cetuximab in definitive chemoradiation for human papillomavirus-unrelated head and neck cancer.Beckham TH, Barney C, Healy E, Wolfe AR, Branstetter A, Yaney A, Riaz N, McBride SM, Tsai CJ, Kang J, Yu Y, Chen L, Sherman E, Dunn L, Pfister DG, Tan J, Rupert R, Bonomi M, Zhang Z, Lobaugh SM, Grecula JC, Mitchell DL, Wobb JL, Miller ED, Blakaj DM, Diavolitsis VM, Lee N, Bhatt AD. Platinum-based regimens versus cetuximab in definitive chemoradiation for human papillomavirus-unrelated head and neck cancer. International Journal Of Cancer. Journal International Du Cancer 2020, 147: 107-115. PMID: 31609479, DOI: 10.1002/ijc.32736.
• Beyond reirradiation: Efficacy and safety of three or more courses of radiation for head and neck malignancies.Xu AJ, Luo L, Leeman JE, Romesser PB, Spielsinger D, Sabol C, Waldenberg T, Brinkman T, Riaz N, McBride S, Kang J, Lee N, Tsai CJ. Beyond reirradiation: Efficacy and safety of three or more courses of radiation for head and neck malignancies. Clinical And Translational Radiation Oncology 2020, 23: 30-34. PMID: 32382663, PMCID: PMC7200775, DOI: 10.1016/j.ctro.2020.04.009.
• Last-line local treatment with the Quad Shot regimen for previously irradiated head and neck cancers.Fan D, Kang JJ, Fan M, Wang H, Lee A, Yu Y, Chen L, Jillian Tsai C, McBride SM, Riaz N, Gelblum DY, Neal BP, Fetten J, Dunn LA, Michel LS, Boyle JO, Cohen MA, Roman BR, Ganly I, Singh B, Wong RJ, Sherman EJ, Lee NY. Last-line local treatment with the Quad Shot regimen for previously irradiated head and neck cancers. Oral Oncology 2020, 104: 104641. PMID: 32182548, PMCID: PMC8480112, DOI: 10.1016/j.oraloncology.2020.104641.
• Outcomes of multimodal therapy in a large series of patients with anaplastic thyroid cancer.Fan D, Ma J, Bell AC, Groen AH, Olsen KS, Lok BH, Leeman JE, Anderson E, Riaz N, McBride S, Ganly I, Shaha AR, Sherman EJ, Tsai CJ, Kang JJ, Lee NY. Outcomes of multimodal therapy in a large series of patients with anaplastic thyroid cancer. Cancer 2020, 126: 444-452. PMID: 31593317, PMCID: PMC7302673, DOI: 10.1002/cncr.32548.
• Outcomes and toxicities of definitive radiotherapy and reirradiation using 3-dimensional conformal or intensity-modulated (pencil beam) proton therapy for patients with nasal cavity and paranasal sinus malignancies.Fan M, Kang JJ, Lee A, Fan D, Wang H, Kitpanit S, Fox P, Sine K, Mah D, McBride SM, Tsai CJ, Riaz N, Dunn LA, Sherman EJ, Michel L, Singh B, Ganly I, Wong RJ, Boyle JO, Cohen MA, Lee NY. Outcomes and toxicities of definitive radiotherapy and reirradiation using 3-dimensional conformal or intensity-modulated (pencil beam) proton therapy for patients with nasal cavity and paranasal sinus malignancies. Cancer 2020, 126: 1905-1916. PMID: 32097507, PMCID: PMC7304541, DOI: 10.1002/cncr.32776.
• The 3 Bs of cancer care amid the COVID-19 pandemic crisis: "Be safe, be smart, be kind"-A multidisciplinary approach increasing the use of radiation and embracing telemedicine for head and neck cancer.Kang JJ, Wong RJ, Sherman EJ, Rybkin A, McBride SM, Riaz N, Tsai CJ, Yu Y, Chen L, Zakeri K, Gelblum DY, Gillespie EF, Cohen MA, Cracchiolo JR, Ganly I, Patel S, Singh B, Boyle JO, Roman BR, Morris LG, Shaha AR, Dunn LA, Ho AL, Fetten JV, Shah JP, Pfister DG, Lee NY. The 3 Bs of cancer care amid the COVID-19 pandemic crisis: "Be safe, be smart, be kind"-A multidisciplinary approach increasing the use of radiation and embracing telemedicine for head and neck cancer. Cancer 2020, 126: 4092-4104. PMID: 32639615, PMCID: PMC7361524, DOI: 10.1002/cncr.33031.
• Trends and Disparities of Proton Therapy Use among Patients with Head and Neck Cancer: Analysis from the National Cancer Database (2005-14).Lee A, Kang J, Yu Y, McBride S, Riaz N, Cohen M, Sherman E, Michel L, Lee N, Tsai CJ. Trends and Disparities of Proton Therapy Use among Patients with Head and Neck Cancer: Analysis from the National Cancer Database (2005-14). International Journal Of Particle Therapy 2019, 5: 1-10. PMID: 31773036, PMCID: PMC6871620, DOI: 10.14338/IJPT-19-00051.1.
• Temporal Lobe Necrosis in Head and Neck Cancer Patients after Proton Therapy to the Skull Base.Kitpanit S, Lee A, Pitter KL, Fan D, Chow JCH, Neal B, Han Z, Fox P, Sine K, Mah D, Dunn LA, Sherman EJ, Michel L, Ganly I, Wong RJ, Boyle JO, Cohen MA, Singh B, Brennan CW, Gavrilovic IT, Hatzoglou V, O'Malley B, Zakeri K, Yu Y, Chen L, Gelblum DY, Kang JJ, McBride SM, Tsai CJ, Riaz N, Lee NY. Temporal Lobe Necrosis in Head and Neck Cancer Patients after Proton Therapy to the Skull Base. International Journal Of Particle Therapy 2020, 6: 17-28. PMID: 32582816, PMCID: PMC7302730, DOI: 10.14338/IJPT-20-00014.1.
• Timing of surgery and adjuvant radiation therapy for sinonasal malignancies: Effect of surgical approach.Xiao R, Joshi RR, Husain Q, Cracchiolo JR, Lee N, Tsai J, Yu Y, Chen L, Kang JJ, McBride S, Riaz N, Roman BR, Ganly I, Tabar V, Gray ST, Cohen MA. Timing of surgery and adjuvant radiation therapy for sinonasal malignancies: Effect of surgical approach. Head & Neck 2019, 41: 3551-3563. PMID: 31294897, PMCID: PMC6742559, DOI: 10.1002/hed.25873.
• First Postprostatectomy Ultrasensitive Prostate-specific Antigen Predicts Survival in Patients with High-risk Prostate Cancer Pathology.Kang JJ, Reiter RE, Steinberg ML, King CR. First Postprostatectomy Ultrasensitive Prostate-specific Antigen Predicts Survival in Patients with High-risk Prostate Cancer Pathology. European Urology Oncology 2018, 1: 378-385. PMID: 31158076, DOI: 10.1016/j.euo.2018.07.008.
• Ultrasensitive prostate specific antigen after prostatectomy reliably identifies patients requiring postoperative radiotherapy.Kang JJ, Reiter RE, Steinberg ML, King CR. Ultrasensitive prostate specific antigen after prostatectomy reliably identifies patients requiring postoperative radiotherapy. The Journal Of Urology 2015, 193: 1532-8. PMID: 25463990, PMCID: PMC4527538, DOI: 10.1016/j.juro.2014.11.017.
• Wrong to be Right: Margin Laterality is an Independent Predictor of Biochemical Failure After Radical Prostatectomy.Kang JJ, Reiter RE, Kummer N, DeKernion J, Steinberg ML, King CR. Wrong to be Right: Margin Laterality is an Independent Predictor of Biochemical Failure After Radical Prostatectomy. American Journal Of Clinical Oncology 2018, 41: 1-5. PMID: 26237192, PMCID: PMC6946377, DOI: 10.1097/COC.0000000000000216.
• Pelvic nodal dosing with registration to the prostate: implications for high-risk prostate cancer patients receiving stereotactic body radiation therapy.Kishan AU, Lamb JM, Jani SS, Kang JJ, Steinberg ML, King CR. Pelvic nodal dosing with registration to the prostate: implications for high-risk prostate cancer patients receiving stereotactic body radiation therapy. International Journal Of Radiation Oncology, Biology, Physics 2015, 91: 832-9. PMID: 25752398, DOI: 10.1016/j.ijrobp.2014.11.035.